[Federal Register Volume 67, Number 207 (Friday, October 25, 2002)]
[Notices]
[Pages 65537-65538]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-27259]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

International Trade Administration

[A-570-853]


Bulk Aspirin from the People's Republic of China: Final Results 
of Changed Circumstances Review

AGENCY: Import Administration, International Trade Administration, 
Department of Commerce.

ACTION: Notice of Final Results of Changed Circumstances Antidumping 
Duty Administrative Review.

-----------------------------------------------------------------------

SUMMARY: On August 7, 2002, the Department of Commerce published a 
notice of preliminary results of its changed circumstances review in 
bulk aspirin from the People's Republic of China examining whether 
Jilin Henghe Pharmaceutical is the successor-in-interest to Jilin 
Pharmaceutical Company Ltd. and Jilin Pharmaceutical Import and Export 
Corporation. We have now completed the changed circumstances review and 
determine Jilin Henghe Pharmaceutical to be the successor-in-interest 
to Jilin Pharmaceutical Company Ltd. and Jilin Pharmaceutical Import 
and Export Corporation.

EFFECTIVE DATE: October 25, 2002.

FOR FURTHER INFORMATION CONTACT: Julie Santoboni or Cole Kyle, Import 
Administration, International Trade Administration, U.S. Department of 
Commerce, 14th Street and Constitution Avenue, NW, Washington, DC 
20230; telephone (202) 482-4194 and (202) 482-1503, respectively.

SUPPLEMENTARY INFORMATION:

Applicable Statute

    Unless otherwise indicated, all citations to the Tariff Act of 
1930, as amended (the ``Act''), are references to the provisions 
effective January 1, 1995, the effective date of the amendments made to 
the Act by the Uruguay Round Agreements Act. In addition, unless 
otherwise indicated, all citations to the Department of Commerce's 
(``the Department's'') regulations are to 19 CFR Part 351 (2001).

Background:

    On August 7, 2002, in accordance with Section 751(b) of the Act and 
19 CFR 351.216 and 351.221(c)(3), the Department published its 
preliminary results in the Federal Register, preliminarily finding 
Jilin Henghe Pharmaceutical (``Jilin Henghe'') to be the successor-in-
interest to Jilin Pharmaceutical Company Ltd. and Jilin Pharmaceutical 
Import and Export Corporation (collectively, ``Jilin Pharmaceutical''). 
We invited interested parties to comment on these findings. No comments 
were received (see Bulk Aspirin from the People's Republic of China: 
Preliminary Results of Antidumping Duty Administrative Review and 
Changed Circumstances Review, 67 FR 51167) (``Preliminary Results'').

Scope of the Review

    The product covered by this review is bulk acetylsalicylic acid, 
commonly referred to as bulk aspirin, whether or not in pharmaceutical 
or compound form, not put up in dosage form (tablet, capsule, powders 
or similar form for direct human consumption). Bulk aspirin may be 
imported in two forms, as pure ortho-acetylsalicylic acid or as mixed 
ortho-acetylsalicylic acid. Pure ortho-acetylsalicylic acid can be 
either in crystal form or granulated into a fine powder (pharmaceutical 
form). This product has the chemical formula C9H8O4. It is defined by 
the official monograph of the United States Pharmacopoeia 23 (``USP''). 
It is currently classifiable under the Harmonized Tariff Schedule of 
the United States (``HTSUS'') subheading 2918.22.1000.
    Mixed ortho-acetylsalicylic acid consists of ortho-acetylsalicylic 
acid combined with other inactive substances such as starch, lactose, 
cellulose, or coloring materials and/or other active substances. The 
presence of other active substances must be in concentrations less than 
that specified for particular nonprescription drug combinations of 
aspirin and active substances as published in the Handbook of 
Nonprescription Drugs, eighth edition, American Pharmaceutical 
Association. This product is currently classifiable under HTSUS 
subheading 3003.90.0000.
    Although the HTSUS subheadings are provided for convenience and 
customs purposes, the written description of the merchandise under 
review is dispositive.

Final Results of Review

    Because we received no comments on the preliminary results, for the 
reasons stated in the Preliminary Results and based on the facts on the 
record, we find Jilin Henghe to be the successor-in-interest to Jilin 
Pharmaceutical for antidumping duty cash deposit purposes. In order to 
make this determination, we examined the management structure of Jilin 
Henghe and Jilin Pharmaceutical, including, but not limited to, 
financial statements, stock purchase agreements, sales documents and 
organizational charts. Since the record shows that Jilin Henghe 
maintained the same management among other things, we determine that 
Jilin Henghe is the successor-in-interest to Jilin Pharmaceutical.
    Jilin Henghe will be assigned the same antidumping duty cash-
deposit rate with respect to the subject merchandise as Jilin 
Pharmaceutical, its predecessor company. This cash deposit requirement 
will be effective upon publication of this notice of final results of 
changed circumstances review for all shipments of the subject 
merchandise entered, or withdrawn from warehouse, for consumption on or 
after the publication date. This cash deposit rate shall remain in 
effect until publication of the final results of the next 
administrative review.

[[Page 65538]]

    This determination is issued and published in accordance with 
sections 751(b)(1) and 777(I)(1) of the Act.

    Dated: October 18, 2002.
Joseph A. Spetrini,
Acting Assistant Secretary for Import Administration.
[FR Doc. 02-27259 Filed 10-24-02; 8:45 am]
BILLING CODE 3510-DS-S